BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010;125:377-81. [PMID: 20079523 DOI: 10.1016/j.thromres.2009.11.034] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Kong J, Sun T, Li G, Szeto FL, Liu W, Deb DK, Wang Y, Zhao Q, Thadhani R, Li YC. 1,25-Dihydroxyvitamin D₃ suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-κB activation. Arch Biochem Biophys 2011;507:241-7. [PMID: 21176770 DOI: 10.1016/j.abb.2010.12.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
2 Boye A, Wu C, Jiang Y, Wang J, Wu J, Yang X, Yang Y. Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism. Journal of Ethnopharmacology 2015;169:219-28. [DOI: 10.1016/j.jep.2015.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
3 Florian M, Yan J, Ulhaq S, Coughlan M, Laziyan M, Willmore W, Jin X. Northern contaminant mixtures induced morphological and functional changes in human coronary artery endothelial cells under culture conditions typifying high fat/sugar diet and ethanol exposure. Toxicology 2013;313:103-12. [DOI: 10.1016/j.tox.2013.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Wu C, Kan H, Hu M, Liu X, Boye A, Jiang Y, Wu J, Wang J, Yang X, Yang Y. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF-β/TβR and Imp7/8. Exp Ther Med 2018;16:1052-60. [PMID: 30112050 DOI: 10.3892/etm.2018.6292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kronbichler A, Oelzner P, Syrbe G, Lopatta E, Wolf G, Neumann T. Bilateral pulmonary embolism in twins with PAI-1 4G/5G gene polymorphism: a case report. Wien Klin Wochenschr 2014;126:53-5. [DOI: 10.1007/s00508-013-0443-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Rep 2018;25:2177-2191.e7. [PMID: 30463014 DOI: 10.1016/j.celrep.2018.10.082] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
7 Carter JC, Church FC. Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System. J Oncol 2011;2011:594258. [PMID: 22131991 DOI: 10.1155/2011/594258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, Shen N, Rajendran S, Cutter A, Cheng YH, Chen YT, Cong J, Spinosa PC, Yoon E, Luker KE, Luker GD. Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer. Mol Cancer Res 2019;17:1142-54. [PMID: 30718260 DOI: 10.1158/1541-7786.MCR-18-0836] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
9 Chen H, Zheng D, Davids J, Bartee MY, Dai E, Liu L, Petrov L, Macaulay C, Thoburn R, Sobel E, Moyer R, McFadden G, Lucas A. Viral serpin therapeutics from concept to clinic. Methods Enzymol 2011;499:301-29. [PMID: 21683260 DOI: 10.1016/B978-0-12-386471-0.00015-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
10 Hu X, Rui W, Wu C, He S, Jiang J, Zhang X, Yang Y. Compound Astragalus and Salvia miltiorrhiza extracts suppress hepatocarcinogenesis by modulating transforming growth factor-β/Smad signaling. J Gastroenterol Hepatol 2014;29:1284-91. [PMID: 24329763 DOI: 10.1111/jgh.12490] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
11 Gopal S, Garibaldi S, Goglia L, Polak K, Palla G, Spina S, Genazzani AR, Genazzani AD, Simoncini T. Estrogen regulates endothelial migration via plasminogen activator inhibitor (PAI-1). Mol Hum Reprod 2012;18:410-6. [PMID: 22389473 DOI: 10.1093/molehr/gas011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ren F, Shi H, Zhang G, Zhang R. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res. 2013;32:60. [PMID: 23988121 DOI: 10.1186/1756-9966-32-60] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Trelle MB, Madsen JB, Andreasen PA, Jørgensen TJD. Local Transient Unfolding of Native State PAI-1 Associated with Serpin Metastability. Angew Chem Int Ed 2014;53:9751-4. [DOI: 10.1002/anie.201402796] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
14 Paltseva EM, Semenova TS, Zhigalova SB, Pestin IS, Shertsinger AG. [Expression of plasminogen activator system components in the gastric mucosa in portal hypertensive gastropathy]. Arkh Patol 2015;77:16-21. [PMID: 26027394 DOI: 10.17116/patol201577216-21] [Reference Citation Analysis]
15 Eftedal I, Jørgensen A, Røsbjørgen R, Flatberg A, Brubakk AO. Early genetic responses in rat vascular tissue after simulated diving. Physiol Genomics 2012;44:1201-7. [PMID: 23132759 DOI: 10.1152/physiolgenomics.00073.2012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
16 Rui W, Xie L, Liu X, He S, Wu C, Zhang X, Zhang L, Yang Y. Compound Astragalus and Salvia miltiorrhiza extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and PAI-1 mRNA transcription. J Ethnopharmacol. 2014;151:198-209. [PMID: 24247078 DOI: 10.1016/j.jep.2013.10.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
17 Viswanathan K, Bot I, Liu L, Dai E, Turner PC, Togonu-Bickersteth B, Richardson J, Davids JA, Williams JM, Bartee MY, Chen H, van Berkel TJ, Biessen EA, Moyer RW, Lucas AR. Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro. PLoS One 2012;7:e44694. [PMID: 23049756 DOI: 10.1371/journal.pone.0044694] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
18 Landrigan A, Yiu G, Agarwal K, Utz PJ. Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion. Leuk Lymphoma 2012;53:166-8. [PMID: 21780996 DOI: 10.3109/10428194.2011.606944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Cardenas JC, Owens AP 3rd, Krishnamurthy J, Sharpless NE, Whinna HC, Church FC. Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler Thromb Vasc Biol 2011;31:827-33. [PMID: 21233453 DOI: 10.1161/ATVBAHA.110.221721] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
20 Zhao R, Le K, Moghadasian MH, Shen GX. Regulatory role of NADPH oxidase in glycated LDL-induced upregulation of plasminogen activator inhibitor-1 and heat shock factor-1 in mouse embryo fibroblasts and diabetic mice. Free Radical Biology and Medicine 2013;61:18-25. [DOI: 10.1016/j.freeradbiomed.2013.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Engstler AJ, Frahnow T, Kruse M, Pfeiffer AFH, Bergheim I. Plasminogen Activator Inhibitor-1 is Regulated Through Dietary Fat Intake and Heritability: Studies in Twins. Twin Res Hum Genet 2017;20:338-48. [DOI: 10.1017/thg.2017.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 McEachron TA, Church FC, Mackman N. Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. Blood Coagul Fibrinolysis. 2011;22:576-582. [PMID: 21799402 DOI: 10.1097/mbc.0b013e3283497647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Rubina KA, Sysoeva VY, Zagorujko EI, Tsokolaeva ZI, Kurdina MI, Parfyonova YV, Tkachuk VA. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Arch Dermatol Res 2017;309:433-42. [DOI: 10.1007/s00403-017-1738-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
24 Chang Y, Mahadeva R, Patschull AO, Nobeli I, Ekeowa UI, Mckay AR, Thalassinos K, Irving JA, Haq I, Nyon MP, Christodoulou J, Ordóñez A, Miranda E, Gooptu B. Targeting Serpins in High-Throughput and Structure-Based Drug Design. Serpin Structure and Evolution. Elsevier; 2011. pp. 139-75. [DOI: 10.1016/b978-0-12-385950-1.00008-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
25 Cardenas J, Rein-smith C, Church F. Overview of Blood Coagulation and the Pathophysiology of Blood Coagulation Disorders. Encyclopedia of Cell Biology. Elsevier; 2016. pp. 714-22. [DOI: 10.1016/b978-0-12-394447-4.10079-3] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
26 Bu HQ, Shen F, Cui J. The inhibitory effect of oridonin on colon cancer was mediated by deactivation of TGF-β1/Smads-PAI-1 signaling pathway in vitro and vivo. Onco Targets Ther 2019;12:7467-76. [PMID: 31686852 DOI: 10.2147/OTT.S220401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Benton RL, Hagg T. Vascular Pathology as a Potential Therapeutic Target in SCI. Transl Stroke Res 2011;2:556-74. [PMID: 24323683 DOI: 10.1007/s12975-011-0128-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chu Y, Bucci JC, Peterson CB. Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1. Protein Sci 2021;30:597-612. [PMID: 33345392 DOI: 10.1002/pro.4017] [Reference Citation Analysis]
29 Reuland CJ, Church FC. Synergy between plasminogen activator inhibitor-1, α-synuclein, and neuroinflammation in Parkinson's disease. Med Hypotheses 2020;138:109602. [PMID: 32035284 DOI: 10.1016/j.mehy.2020.109602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
30 Declerck PJ, Gils A, De Taeye B. Use of mouse models to study plasminogen activator inhibitor-1. Methods Enzymol 2011;499:77-104. [PMID: 21683250 DOI: 10.1016/B978-0-12-386471-0.00005-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
31 Chu Y, Bucci JC, Peterson CB. Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin. Protein Sci 2020;29:494-508. [PMID: 31682300 DOI: 10.1002/pro.3770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M. Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget 2016;7:3341-56. [PMID: 26657503 DOI: 10.18632/oncotarget.6490] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
33 Jamar G, Pisani LP, Oyama LM, Belote C, Masquio DC, Furuya VA, Carvalho-Ferreira JP, Andrade-Silva SG, Dâmaso AR, Caranti DA. Is the neck circumference an emergent predictor for inflammatory status in obese adults? Int J Clin Pract 2013;67:217-24. [PMID: 23409690 DOI: 10.1111/ijcp.12041] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
34 Hagelgans A, Menschikowski M, Fuessel S, Nacke B, Arneth BM, Wirth MP, Siegert G. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms. Exp Mol Pathol 2013;94:458-65. [PMID: 23541763 DOI: 10.1016/j.yexmp.2013.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
35 Hjorth M, Norheim F, Meen AJ, Pourteymour S, Lee S, Holen T, Jensen J, Birkeland KI, Martinov VN, Langleite TM, Eckardt K, Drevon CA, Kolset SO. The effect of acute and long-term physical activity on extracellular matrix and serglycin in human skeletal muscle. Physiol Rep 2015;3:e12473. [PMID: 26290530 DOI: 10.14814/phy2.12473] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
36 Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med 2019;23:2984-94. [PMID: 30734495 DOI: 10.1111/jcmm.14205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
37 Urano T, Suzuki Y, Iwaki T, Sano H, Honkura N, Castellino FJ. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis. Curr Drug Targets 2019;20:1695-701. [PMID: 31309890 DOI: 10.2174/1389450120666190715102510] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
38 Zheng Y, Liu T, Li Q, Li J. Integrated analysis of long non-coding RNAs (lncRNAs) and mRNA expression profiles identifies lncRNA PRKG1-AS1 playing important roles in skeletal muscle aging. Aging (Albany NY) 2021;13:15044-60. [PMID: 34051073 DOI: 10.18632/aging.203067] [Reference Citation Analysis]
39 Iacoviello L, Agnoli C, De Curtis A, di Castelnuovo A, Giurdanella MC, Krogh V, Mattiello A, Matullo G, Sacerdote C, Tumino R, Vineis P, de Gaetano G, Panico S, Donati MB. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study. BMJ Open 2013;3:e003725. [PMID: 24231461 DOI: 10.1136/bmjopen-2013-003725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
40 Dariusz S, Agnieszka M, Elzbieta R, Danuta ON, Maciej Z, Piotr D, Nowicki M. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol 2012;163:193-9. [PMID: 22525297 DOI: 10.1016/j.ejogrb.2012.03.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Carter JC, Church FC. Mature breast adipocytes promote breast cancer cell motility. Exp Mol Pathol 2012;92:312-7. [PMID: 22445926 DOI: 10.1016/j.yexmp.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
42 Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat 2013;23:801-15. [PMID: 23521527 DOI: 10.1517/13543776.2013.782393] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]